GlassScriptPhysician profile
Kambiz Bral
NPI 1568452928
$5,496.01
in general payments reported to CMS, 2019-2025
28 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $273 · 2021: $649 · 2022: $738 · 2023: $1,172 · 2024: $1,105 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.63 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,191.60 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $349.40 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.21 | 2021-2025 | Xifaxan, Plenvu |
| Allergan, INC. | $257.18 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $236.11 | 2021-2023 | |
| Genzyme Corporation | $224.56 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.57 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $167.34 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $146.60 | 2024-2025 | Rezdiffra |
| Celgene Corporation | $121.21 | 2021-2023 | Zeposia |
| Pfizer INC. | $115.63 | 2023-2025 | |
| Ardelyx, INC. | $105.73 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $80.95 | 2020-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $80.63 | 2021-2024 | Clenpiq, Rebyota |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $70.60 | 2023-2024 | Capsocam Plus |
| Qol Medical, LLC | $61.49 | 2025 | Sucraid |
| Gilead Sciences, INC. | $53.98 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $42.17 | 2020-2025 | |
| Braintree Laboratories, INC. | $26.08 | 2019 | |
| Shire North American Group INC | $24.29 | 2019 | |
| Organon LLC | $22.90 | 2021 | |
| Redhill Biopharma INC. | $20.63 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.03 | 2020 | |
| Mauna Kea Technologies, INC. | $14.04 | 2020 | |
| Daiichi Sankyo INC. | $13.78 | 2019 | |
| Shionogi INC | $12.61 | 2019 | |
| Medtronic, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kambiz Bral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.